Last reviewed · How we verify

New England Retina Associates — Portfolio Competitive Intelligence Brief

New England Retina Associates pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Topical Prednisolone Acetate 1% Topical Prednisolone Acetate 1% marketed Topical corticosteroid Glucocorticoid receptor Ophthalmology
Ranibizumab injection and TTT - ICG based Ranibizumab injection and TTT - ICG based phase 3 VEGF inhibitor (monoclonal antibody fragment) combined with thermal ablation guidance VEGF-A Ophthalmology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
  2. Al-Azhar University · 1 shared drug class
  3. All India Institute of Medical Sciences, Bhubaneswar · 1 shared drug class
  4. Apotex Inc. · 1 shared drug class
  5. Astellas Pharma Inc · 1 shared drug class
  6. Astion Pharma A/S · 1 shared drug class
  7. AstraZeneca · 1 shared drug class
  8. Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for New England Retina Associates:

Cite this brief

Drug Landscape (2026). New England Retina Associates — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/new-england-retina-associates. Accessed 2026-05-17.

Related